Schneider, S.A.; D’Amora, P.; Evans, S.S.; Kent, P.; Stockwell, T.; Bakaya, V.S.; Bernard, P.J.; Francisco, F.R.; Torres, L.; Henry, J., Jr.;
et al. Functional Precision Oncology in Fibrolamellar Carcinoma: Ex Vivo Identification of Therapeutic Vulnerabilities. Cancers 2026, 18, 1744.
https://doi.org/10.3390/cancers18111744
AMA Style
Schneider SA, D’Amora P, Evans SS, Kent P, Stockwell T, Bakaya VS, Bernard PJ, Francisco FR, Torres L, Henry J Jr.,
et al. Functional Precision Oncology in Fibrolamellar Carcinoma: Ex Vivo Identification of Therapeutic Vulnerabilities. Cancers. 2026; 18(11):1744.
https://doi.org/10.3390/cancers18111744
Chicago/Turabian Style
Schneider, Sabina A., Paulo D’Amora, Steven S. Evans, Paul Kent, Tom Stockwell, Vikrant S. Bakaya, Paula J. Bernard, Federico R. Francisco, Luisa Torres, John Henry, Jr.,
and et al. 2026. "Functional Precision Oncology in Fibrolamellar Carcinoma: Ex Vivo Identification of Therapeutic Vulnerabilities" Cancers 18, no. 11: 1744.
https://doi.org/10.3390/cancers18111744
APA Style
Schneider, S. A., D’Amora, P., Evans, S. S., Kent, P., Stockwell, T., Bakaya, V. S., Bernard, P. J., Francisco, F. R., Torres, L., Henry, J., Jr., Silva, I. D. C. G., & Nagourney, R. A.
(2026). Functional Precision Oncology in Fibrolamellar Carcinoma: Ex Vivo Identification of Therapeutic Vulnerabilities. Cancers, 18(11), 1744.
https://doi.org/10.3390/cancers18111744
